FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 695 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... December 12, 2024 Low-Dose Aspirin Could be an Alternative to Colectomy for Preventing Colorectal... April 8, 2021 As Use of Genomic Data Expands in Cancer Care, Patients Share... December 3, 2019 Load more HOT NEWS FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute... New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients
